Publications

@article{Thomas2025-td,

title = {Evolution of preclinical models for glioblastoma modelling and drug screening},

author = {Grace Thomas and Ruman Rahman},

doi = {10.1007/s11912-025-01672-4},

year  = {2025},

date = {2025-05-01},

urldate = {2025-05-01},

journal = {Curr. Oncol. Rep.},

volume = {27},

number = {5},

pages = {601\textendash624},

publisher = {Springer Science and Business Media LLC},

abstract = {PURPOSE OF REVIEW: Isocitrate dehydrogenase wild-type 

 glioblastoma is an extremely aggressive and fatal primary brain 

 tumour, characterised by extensive heterogeneity and diffuse 

 infiltration of brain parenchyma. Despite multimodal treatment 

 and diverse research efforts to develop novel therapies, there 

 has been limited success in improving patient outcomes. 

 Constructing physiologically relevant preclinical models is 

 essential to optimising drug screening processes and identifying 

 more effective treatments. RECENT FINDINGS: Traditional in-vitro 

 models have provided critical insights into glioblastoma 

 pathophysiology; however, they are limited in their ability to 

 recapitulate the complex tumour microenvironment and its 

 interactions with surrounding cells. In-vivo models offer a more 

 physiologically relevant context, but often do not fully 

 represent human pathology, are expensive, and time-consuming. 

 These limitations have contributed to the low translational 

 success of therapies from trials to clinic. Organoid and 

 glioblastoma-on-a-chip technology represent significant advances 

 in glioblastoma modelling and enable the replication of key 

 features of the human tumour microenvironment, including its 

 structural, mechanical, and biochemical properties. Organoids 

 provide a 3D system that captures cellular heterogeneity and 

 tumour architecture, while microfluidic chips offer dynamic 

 systems capable of mimicking vascularisation and nutrient 

 exchange. Together, these technologies hold tremendous potential 

 for high throughput drug screening and personalised, precision 

 medicine. This review explores the evolution of preclinical 

 models in glioblastoma modelling and drug screening, emphasising 

 the transition from traditional systems to more advanced 

 organoid and microfluidic platforms. Furthermore, it aims to 

 evaluate the advantages and limitations of both traditional and 

 next-generation models, investigating their combined potential 

 to address current challenges by integrating complementary 

 aspects of specific models and techniques.},

keywords = {Glioblastoma, Glioblastoma-on-a-chip, Microfluids, Organoids, Preclinical model},

pubstate = {published},

tppubtype = {article}

}